These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 17647245)

  • 21. Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis.
    Batist G; Harris L; Azarnia N; Lee LW; Daza-Ramirez P
    Anticancer Drugs; 2006 Jun; 17(5):587-95. PubMed ID: 16702817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trastuzumab and survival of patients with metastatic breast cancer.
    Kast K; Schoffer O; Link T; Forberger A; Petzold A; Niedostatek A; Werner C; Klug SJ; Werner A; Gatzweiler A; Richter B; Baretton G; Wimberger P
    Arch Gynecol Obstet; 2017 Aug; 296(2):303-312. PubMed ID: 28616827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women.
    Weiner CM; Mathewos A; Addissie A; Ayele W; Aynalem A; Wondemagegnehu T; Wienke A; Jemal A; Zerche P; Thomssen C; Seidler A; Kantelhardt EJ
    Breast; 2018 Dec; 42():23-30. PubMed ID: 30149234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French Population-Based Study.
    Marshall EM; Bertaut A; Desmoulins I; Darut-Jouve A; Ponnelle T; Poillot ML; Beltjens F; Arveux P
    Breast J; 2017 Mar; 23(2):138-145. PubMed ID: 27935232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
    Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
    Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.
    Lin PL; Hao Y; Xie J; Li N; Ohashi E; Koo V; Wu EQ
    Expert Opin Pharmacother; 2015; 16(14):2101-11. PubMed ID: 26290278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescribing practices of endocrine therapy for ductal carcinoma
    Chaudhry AT; Koulis TA; Speers C; Olson RA
    Curr Oncol; 2018 Apr; 25(2):133-138. PubMed ID: 29719429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-Line Palliative HER2-Targeted Therapy in HER2-Positive Metastatic Breast Cancer Is Less Effective After Previous Adjuvant Trastuzumab-Based Therapy.
    Rier HN; Levin MD; van Rosmalen J; Bos MMEM; Drooger JC; de Jong P; Portielje JEA; Elsten EMP; Ten Tije AJ; Sleijfer S; Jager A
    Oncologist; 2017 Aug; 22(8):901-909. PubMed ID: 28533475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence proportions and prognosis of breast cancer patients with bone metastases at initial diagnosis.
    Gong Y; Zhang J; Ji P; Ling H; Hu X; Shao ZM
    Cancer Med; 2018 Aug; 7(8):4156-4169. PubMed ID: 29984914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
    Hao Y; Meyer N; Song X; Shi N; Johnson W; Juneau P; Yardley DA; Willemann Rogerio J
    Curr Med Res Opin; 2015 Feb; 31(2):275-88. PubMed ID: 25365467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal adjuvant endocrine treatment of ER+/HER2+ breast cancer patients by age at diagnosis: A population-based cohort study.
    Dackus GMHE; Jóźwiak K; Sonke GS; van der Wall E; van Diest PJ; Hauptmann M; Siesling S; Linn SC
    Eur J Cancer; 2018 Feb; 90():92-101. PubMed ID: 29274928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study.
    Nichol AM; Chan EK; Lucas S; Smith SL; Gondara L; Speers C; Tyldesley S
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):829-839. PubMed ID: 28602413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival.
    Rossi M; Carioli G; Bonifazi M; Zambelli A; Franchi M; Moja L; Zambon A; Corrao G; La Vecchia C; Zocchetti C; Negri E
    Eur J Cancer; 2016 Jan; 52():41-9. PubMed ID: 26630533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
    Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
    Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
    Statler AB; Hobbs BP; Wei W; Gupta A; Blake CN; Nahleh ZA
    Sci Rep; 2019 Dec; 9(1):18126. PubMed ID: 31792304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
    Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
    Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.